HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Conditions
Keywords
Neratinib, Trastuzumab
Brief summary
This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.
Detailed description
PRIMARY OBJECTIVE: I. To characterize the incidence and severity of diarrhea in patients with early stage breast cancer receiving adjuvant neratinib with or without trastuzumab in the setting of anti-diarrheal strategies. SECONDARY OBJECTIVES: I. To evaluate the incidence of grade 3 or higher diarrhea using the dose-escalation strategy and anti-diarrhea medications as needed (prn) in patients who received prior trastuzumab emtansine (T-DM1). II. To assess neratinib adherence, holds, delays, and early discontinuation throughout the course of study therapy which includes patients receiving neratinib for \> 1 year. III. To assess overall toxicity including constipation and cardiac toxicity with concomitant neratinib and trastuzumab. OUTLINE: This is a dose-escalation study of neratinib. Patients receive one of the following treatment regimen: NERATINIB MONOTHERAPY: Patients receive neratinib orally (PO) once daily (QD) on days 1-21. Cycles repeats every 21 days for up to 55 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive loperamide and/or diphenoxylate hydrochloride/atropine sulfate as needed per physician discretion for symptom management. NERATINIB AND TRASTUZUMAB: Patients receive neratinib PO QD on days 1-21. Patients also receive trastuzumab maintenance therapy as determined by treating physician. Treatment repeats every 21 days for up to 55 weeks in the absence of disease progression or unacceptable toxicity. After completion of trastuzumab treatment, patients may continue on neratinib monotherapy for the remainder of the 55 weeks. Patients may receive loperamide and/or diphenoxylate hydrochloride/atropine sulfate as needed per physician discretion for symptom management. After completion of studies treatment, patients are followed up for 28 days.
Interventions
DRUGNeratinib
Given orally (PO)
BIOLOGICALTrastuzumab
Given Intravenously (IV)
DRUGLoperamide
Given PO
DRUGCrofelemer
Given PO
Allowed for participants experiencing refractory diarrhea
Sponsors
Puma Biotechnology, Inc.
University of California, San Francisco
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years * Histologically confirmed clinical or pathological stage 2 through stage 3c primary adenocarcinoma of the breast * Documented human epidermal growth factor receptor 2 (HER2) overexpression or gene-amplified tumor by a validated approved method * Patients can have hormone receptor (HR)+ or HR-negative disease * Concurrent adjuvant endocrine therapy and bone-modifying agents is allowed * Patients can be premenopausal or postmenopausal * Completion of neoadjuvant or adjuvant chemotherapy * Completion of adjuvant locoregional radiation, if indicated, is required prior to starting study treatment * Histologically confirmed clinical or pathological stage 2 through stage 3c primary adenocarcinoma of the breast * Documented HER2 overexpression or gene-amplified tumor by a validated approved method * Patients can have hormone receptor (HR)+ or HR-negative disease * Concurrent adjuvant endocrine therapy and bone-modifying agents is allowed * Patients can be premenopausal or postmenopausal * Completion of neoadjuvant or adjuvant chemotherapy * Completion of adjuvant locoregional radiation, if indicated, is required prior to starting study treatment * At the time of study enrollment, patients can still be receiving adjuvant trastuzumab monotherapy or be within 2 years of completing adjuvant trastuzumab +/- pertuzumab maintenance, or adjuvant T-DM1. * Patients who are within 2 years of completing trastuzumab +/- pertuzumab or T-DM1 will receive neratinib monotherapy (and not neratinib + trastuzumab) * Adjuvant T-DM1 is the standard of care for patients who have residual disease after neoadjuvant chemotherapy. Patients with residual disease after neoadjuvant chemotherapy should receive T-DM1 before enrolling on the study. If not, the option of T-DM1 should be discussed with the patient * Clinically no evidence of metastatic disease at the time of study entry. Patients with fully resected locoregional recurrence with no evidence of disease are eligible * Left ventricular ejection fraction (LVEF) \>= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO) * Eastern Cooperative Oncology Group (ECOG) status of 0 to 1 * Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause; (women are considered postmenopausal if they are \>= 12 months without menses, in the absence of endocrine or anti-endocrine therapies) * Trastuzumab can cause embryo-fetal harm when administered during pregnancy and the effects of neratinib on the developing human fetus are unknown. Women of child-bearing potential must agree and commit to use of a highly effective double-barrier method of contraception (e.g., a combination of male condom with an intravaginal device such as the cervical cap, diaphragm, or vaginal sponge with spermicide) or a non-hormonal method, from the signing of informed consent until 28 days after the last dose of neratinib and 7 months after the last dose of trastuzumab, or consent to total sexual abstinence (abstinence must occur from randomization and continue for 28 days after the last dose of neratinib and 7 months after the last dose of trastuzumab). Men without confirmed vasectomy must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of investigational products, or consent to total sexual abstinence (abstinence must occur from randomization and continue for 3 months after the last dose of study medication) * Recovery (i.e., to grade 1 or baseline) from all clinically significant adverse event (AE)s related to prior therapies (excluding alopecia, neuropathy, and nail changes) * Provide written, informed consent to participate in the study and follow the study procedures
Exclusion criteria
* Clinical or radiologic evidence of metastatic disease prior to or at the time of study entry. Locoregional recurrent disease that is resected is allowed * Currently receiving chemotherapy, radiation therapy, investigational immunotherapy, or investigational biotherapy for breast cancer * Major surgery (including breast surgery) within \< 30 days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy \< 14 days prior to the initiation of investigational products (except adjuvant endocrine therapy) * Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of \>= 2; including individuals who currently use digitalis, beta-blockers, or calcium channel blockers specifically for congestive heart failure), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia * Corrected QT (QTc) interval \> 0.450 seconds (males) or \> 0.470 seconds (females), or known history of QTc prolongation or Torsade de Pointes (TdP) * Absolute neutrophil count (ANC) =\< 1,000/microliter (uL) * Platelets =\< 100,000/uL * Hemoglobin =\< 9 g/dL * Serum creatinine \>= 1.5 x upper limit of normal (ULN) OR calculated creatinine clearance =\< 30 mL/min for patients with creatinine levels \> 1.5 x institutional ULN \* Creatinine clearance should be calculated per institutional standard * Serum total bilirubin \>= 1.5 x ULN OR direct bilirubin \>= ULN for patients with total bilirubin levels \> 1.5 x ULN * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (\[SGOT)) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase (SGPT)) \>= 2.5 x ULN * Second malignancy for which the patient will be receiving active treatment during the time of study participation. * Currently pregnant or breast-feeding * Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or grade \>= 2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v.4.0) diarrhea of any etiology at baseline) * Clinically active infection with hepatitis B or hepatitis C virus * Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that could, in the investigator's judgment, make the patient inappropriate for this study * Known hypersensitivity to any component of the investigational products * Unable or unwilling to swallow tablets
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Grade 3 or Greater Diarrhea | Up to 6 weeks | Percentage of participants with clinically assessed grade 3 or greater diarrhea reported within the first 2 cycles (each cycle is 21 days) of neratinib while using anti-diarrheal strategies. Reports of diarrhea will be graded according to NCI CTCAE version 4.0. |
| Percentage of Participants Who Did Not Require Loperamide During Multiple Cycles of Treatment | Up to 55 weeks | Percentage of participants who did not require loperamide during cancer treatment for at least 5 cycles will be reported. |
| Percentage of Participants Who Discontinued Anti-diarrheal Medications for Multiple Cycles of Treatment | Up to 55 weeks | The percentage of participants who discontinued all anti-diarrheal medications during cancer treatment for at least 5 cycles will be reported. |
| Percentage of Participants With Treatment-related Adverse Events | Up to 55 weeks | Percentage of participants with reported serious adverse events and adverse events of interest of any grade that have been determined to be related to the anti-diarrhea treatment will be reported by worst grade and associated toxicity. |
| Number of Participants With Neratinib Dose Holds | Up to 55 weeks | The number of participants who experienced a dose hold of neratinib during the course of study therapy will be reported |
| Number of Participants Who Discontinued Neratinib Early | Up to 55 weeks | The number of participants who discontinued neratinib earlier than expected during the course of study therapy will be reported |
| Number of Participants With Neratinib Dose-reductions | Up to 55 weeks | The number of participants whose dose was reduced at any time during the course of therapy will be reported |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide Participants will receive 240mg neratinib to be taken continuously in 21-day cycles once a day for up to 55 weeks on study with no rest between cycles unless related to toxicity. Participants will receive Neratinib and may also be prescribed standard of care maintenance adjuvant trastuzumab (duration of maintenance trastuzumab is at the discretion of the treating physician), for up to 55 weeks. If applicable, after the completion of trastuzumab maintenance therapy (determined by treating physician), neratinib may continue as monotherapy to complete a maximum of 55 weeks. Participants will also receive 125mg of prophylactic Crofelemer and 4 mg of prophylactic loperamide as needed in the first 2 cycles. | 7 |
| Adjuvant Neratinib, Loperamide Participants will receive 120 mg of neratinib on days 1-7 with subsequent increase in dose by 40 mg every 7 days until the full dose of 240 mg a day is reached within the first cycle (up to 240mg) to be taken continuously in 21-day cycles once a day for up to 55 weeks on study with no rest between cycles unless related to toxicity. Participants will receive Neratinib and may also be prescribed standard of care maintenance adjuvant trastuzumab (duration of maintenance trastuzumab is at the discretion of the treating physician), for up to 55 weeks. If applicable, after the completion of trastuzumab maintenance therapy (determined by treating physician), neratinib may continue as monotherapy to complete a maximum of 55 weeks. Participants will also receive 4 mg of prophylactic loperamide to be taken as needed. | 4 |
| Total | 11 |
Baseline characteristics
| Characteristic | Total | Adjuvant Neratinib, Loperamide | Adjuvant Neratinib, Crofelemer, Loperamide |
|---|---|---|---|
| Age, Customized 30-39 years old | 1 Participants | 1 Participants | 0 Participants |
| Age, Customized 40-49 years old | 6 Participants | 0 Participants | 6 Participants |
| Age, Customized 50-59 years old | 3 Participants | 3 Participants | 0 Participants |
| Age, Customized 60-69 years old | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 2 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 2 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Hormone receptor positive (HR+) | 11 participants | 4 participants | 7 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 8 Participants | 4 Participants | 4 Participants |
| Region of Enrollment United States | 11 participants | 4 participants | 7 participants |
| Sex: Female, Male Female | 11 Participants | 4 Participants | 7 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 4 |
| other Total, other adverse events | 7 / 7 | 4 / 4 |
| serious Total, serious adverse events | 0 / 7 | 0 / 4 |
Outcome results
Primary
Number of Participants Who Discontinued Neratinib Early
The number of participants who discontinued neratinib earlier than expected during the course of study therapy will be reported
Time frame: Up to 55 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide | Number of Participants Who Discontinued Neratinib Early | 1 Participants |
| Adjuvant Neratinib, Loperamide | Number of Participants Who Discontinued Neratinib Early | 0 Participants |
Primary
Number of Participants With Neratinib Dose Holds
The number of participants who experienced a dose hold of neratinib during the course of study therapy will be reported
Time frame: Up to 55 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide | Number of Participants With Neratinib Dose Holds | 0 Participants |
| Adjuvant Neratinib, Loperamide | Number of Participants With Neratinib Dose Holds | 0 Participants |
Primary
Number of Participants With Neratinib Dose-reductions
The number of participants whose dose was reduced at any time during the course of therapy will be reported
Time frame: Up to 55 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide | Number of Participants With Neratinib Dose-reductions | 3 Participants |
| Adjuvant Neratinib, Loperamide | Number of Participants With Neratinib Dose-reductions | 2 Participants |
Primary
Percentage of Participants Who Did Not Require Loperamide During Multiple Cycles of Treatment
Percentage of participants who did not require loperamide during cancer treatment for at least 5 cycles will be reported.
Time frame: Up to 55 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide | Percentage of Participants Who Did Not Require Loperamide During Multiple Cycles of Treatment | 71 percentage of participants |
| Adjuvant Neratinib, Loperamide | Percentage of Participants Who Did Not Require Loperamide During Multiple Cycles of Treatment | 50 percentage of participants |
Primary
Percentage of Participants Who Discontinued Anti-diarrheal Medications for Multiple Cycles of Treatment
The percentage of participants who discontinued all anti-diarrheal medications during cancer treatment for at least 5 cycles will be reported.
Time frame: Up to 55 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide | Percentage of Participants Who Discontinued Anti-diarrheal Medications for Multiple Cycles of Treatment | 43 percentage of participants |
| Adjuvant Neratinib, Loperamide | Percentage of Participants Who Discontinued Anti-diarrheal Medications for Multiple Cycles of Treatment | 25 percentage of participants |
Primary
Percentage of Participants With Grade 3 or Greater Diarrhea
Percentage of participants with clinically assessed grade 3 or greater diarrhea reported within the first 2 cycles (each cycle is 21 days) of neratinib while using anti-diarrheal strategies. Reports of diarrhea will be graded according to NCI CTCAE version 4.0.
Time frame: Up to 6 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide | Percentage of Participants With Grade 3 or Greater Diarrhea | 29 percentage of participants |
| Adjuvant Neratinib, Loperamide | Percentage of Participants With Grade 3 or Greater Diarrhea | 50 percentage of participants |
Primary
Percentage of Participants With Treatment-related Adverse Events
Percentage of participants with reported serious adverse events and adverse events of interest of any grade that have been determined to be related to the anti-diarrhea treatment will be reported by worst grade and associated toxicity.
Time frame: Up to 55 weeks
Population: All participants experienced only Grade 1, Constipation related to anti-diarrhea medication. No other treatment-related adverse events were reported.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Adjuvant Neratinib, Crofelemer, Loperamide | Percentage of Participants With Treatment-related Adverse Events | 100 percentage of participants |
| Adjuvant Neratinib, Loperamide | Percentage of Participants With Treatment-related Adverse Events | 100 percentage of participants |